pharmacology, therapeutics and medicines management sue ayers advanced pharmacists palliative...
TRANSCRIPT
![Page 1: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/1.jpg)
Pharmacology, Therapeutics and medicines management
Sue Ayers Advanced Pharmacists Palliative Medicine
March 2011
![Page 2: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/2.jpg)
Index of learning outcomes - 1Pharmacokinetics and PharmacodynamicsPharmacogeneticsDose adjustments in frail, elderly and
children Dose adjustment in renal failureDose adjustment in Liver Failure Dose adjustment in disease progression and
at the end of life
![Page 3: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/3.jpg)
Index of learning outcomes - 2Drug formularies in palliative care Managing a pharmacy budget Prescribing issues ( non CDs)Prescribing issues (CDs) CD legislation Unlicensed drugs Drugs beyond licence Drugs in clinical trials
![Page 4: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/4.jpg)
Index of learning outcomes - 3Polypharmacy Understanding medicines Medicine related adverse event reporting Alternative routes of administration Drugs in syringe driversDrug interactions Tolerance, dependence, addiction,
discontinuation reactions Accessing drugs in the community
![Page 5: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/5.jpg)
Pharmacokinetics/dynamicsPharmacokinetics may be simply defined as what the body does to the drug, as opposed to pharmacodynamics which may be defined as what the drug does to the body.
![Page 6: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/6.jpg)
Movement of drugs across cellular barriers To traverse cellular barriers (e.g.
gastrointestinal mucosa, renal tubule, blood–brain barrier, placenta), drugs have to cross lipid membranes.
Drugs cross lipid membranes mainly (a) by passive diffusional transfer and (b) by carrier-mediated transfer.
The main factor for rate of passive diffusional transfer across membranes is a drug’s lipid solubility. Molecular weight less important.
![Page 7: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/7.jpg)
Pharmacokinetics - Processes Distribution - cellular barriers, protein
binding, “compartments”, ADME
![Page 8: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/8.jpg)
Movement of drugs across cellular barriersMany drugs are weak acids or weak bases;
state of ionisation varies with pH according to the Henderson–Hasselbalch equation.
Weak acids or bases - only the uncharged species can diffuse across lipid membranes; this gives rise to pH partition.
pH partition means that weak acids tend to accumulate in compartments of relatively high pH, whereas weak bases do the reverse.
![Page 9: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/9.jpg)
Movement of drugs across cellular barriersCarrier-mediated transport (e.g. in the renal
tubule, blood–brain barrier, gastrointestinal epithelium) is important for some drugs that are chemically related to endogenous substances.
![Page 10: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/10.jpg)
Plasma Protein Binding At therapeutic plasma concentrations many drugs
exist mainly in bound formFree drug in aqueous solution can be less than 1%Albumin – most important. 2 bi9nding sites. Binds
many acidic drugs (warfarin/NSAIDs) and some basic drugs ( TCAs/chlorpromazine)
Beta – globulin and acid glycoprotein – bind basic drugs ( quinine)
Amount bound depends on concentration of free drug
affinity of binding sites concentration of protein
![Page 11: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/11.jpg)
Plasma Protein Binding Usual concentration of albumin is 0.6mmol/l 2 binding sites per molecule – binding capacity for
drugs is 1.2mmol/l Most drugs therapeutic plasma level < 1.2 mmol/l
so binding sites not saturated and fraction unbound not dependant on drug concentration
Important if therapeutic concentration nearing saturation ( sulphonamides and tolbutamide) - doubling dose can more than double free concentration
Displacement from binding sites is only relevant when binding sites saturated ( less important drug interaction)
Extensive protein binding slows elimination ( Met or excretion by glomerular filtration)
![Page 12: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/12.jpg)
Partition into body fat and other tissues Fat is a large, non polar compartment only relevant
for a few drugs Most drugs have a low fat:water partition
coefficient Morphine – lipid soluble enough to enter BBB but
lipid:water partition coefficient is only 0.4 so sequestration into fat not important
Thiopental ( f:w coefficient = 10 ) distributes into fat so no good as an induction anaesthetic
Fat has low blood supply <2% cardiac output – limits drug accumulation when given acutely as slow to accumulate , but chronic administration of lipid soluble drugs ( Benzos) may accumulate ( or insecticides)
![Page 13: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/13.jpg)
Other Tissues drugs bind toMelanin – Chloroquine ( particularly in the
retina) Tetracyclines – bones and teeth Amiodarone – liver and lung
![Page 14: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/14.jpg)
Routes of administration Routes – advantages and disadvantagesFrom intestine -Passive transport mainly rate determined by
ionisation and lipid solubility. Strong bases ( pKa >10) and strong acid ( pKa <3) are not adsorbed as they are sully ionised ( curare)
Carrier – mediated transport . Levodopa ( via phenylalanine carrier) Fluorouracil ( via pyrimidine carrier thyamine and uracil) Iron via carriers in jejunal mucosa and calcium via vitamin D dependant carrier
![Page 15: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/15.jpg)
Factors affecting GI absorption
Motility Splanchnic blood flow ( increased by food) Particle size and formulation ( Extended
release preparations ) Physiochemical properties – milk and
tetracyclines, cholestyramineOral Vancomycin/nystatin
![Page 16: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/16.jpg)
Bioavailability proportion of drug that enters into the
systemic circulation after oral administration doesn't indicate rate of absorption just total
amountUsually a percentage range ( variable! Not
accurate) Drug licensing authorities use bio-
equivalence - ie new substance behaves similarly to another without clinical harm to substitute it. ( Zomorph/MST)
![Page 17: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/17.jpg)
Distribution Body Water ( 50 – 70%) in four compartments Extracellular fluid – plasma 4.5% body weight,
interstitial fluid 16% bw, lymph 1.2% Intracellular fluid 30 – 40% bw Transcellular fluid 2.5%bw - csf, eye, peritoneal,
pleural, synovial and digestive secretionsIn body water drugs exist as free and bound,
ionised and unionised forms depending on Ph Drugs move across compartmentsBBBis particularly important
![Page 18: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/18.jpg)
Blood Brain Barrier Domperidone doesn’t cross –Chemoreceptor Trigger Zone has leaky
barrier – acts there. Can use with parkinson’s patients on dopamine antagonists that do cross BBB
Methylnaltrexone (Relistor) Increased permeability – liver disease,
bradykinin and enkephalins
![Page 19: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/19.jpg)
General Prescribing Prescription forms – types Legal requirements ad best practice:
http://www.nhsbsa.nhs.uk/PrescriptionServices.aspxBNF http://www.medicines.org.uk/emc/ (SPC) Local organisational prescribing policy/guideline/formularyCommissioners’/contractors prescribing policy/guidelines
![Page 20: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/20.jpg)
Volume of distribution ( Vd) The volume of fluid that is required to
contain the total amount ( Q) of drug in the body at the same concentration as that present in the plasma ( Cp)
Vd = Q/Cp Vd tables in PCF3 Plasma volume = 0.05l/kg body weightHeparin Vd 0.05 – 0.1 (mainly in plasma) Extracellular fluid 0.2l/kg Theophylline 0.4 – 0.7
![Page 21: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/21.jpg)
Volume of distribution ( Vd)Total body water 0.55 l/kgEthanol, phenytoin 0.55Paracetamol, diazepam 1-2Morphine, digoxin 2-5Nortriptyline >10Lipid insoluble drugs mainly stay in plasma
and interstitial fluid . Most don’t cross BBBLipid soluble drugs reach all compartments
and may go into fat/tissue ( Vd > total body volume)
![Page 22: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/22.jpg)
Metabolism
http://www.youtube.com/watch?v=xtI0pMEZy7cMainly liver ( gut/lungs) –”First pass metabolism” Phase I reactions (also termed nonsynthetic reactions) may occur by oxidation, reduction, hydrolysis, cyclization, and decyclization, addition of oxygen or removal of hydrogencarried out by mixed function oxidases, often in the liver. These oxidative reactions typically involve a cytochrome P450 ( CYP3a4 metabolises 50% drugs, then 2D6 and 2C9 or 8 ) Can get genetic variation
![Page 23: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/23.jpg)
Metabolism Phase II reactionsusually known as conjugation reactions (e.g., with
glucuronic acid, sulfonates, glutathione or amino acids) are usually detoxication in nature.
Products of conjugation reactions have increased molecular weight and are usually inactive unlike Phase I reactions which often produce active metabolites.
Morphine goes straight to Phase II - M3G and M6G In general, drugs are metabolized more slowly in
fetal, neonatal and elderly humans and animals than in adults
Can get genetic variation
![Page 24: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/24.jpg)
Metabolism – drug interactions and genetics Enzyme inducers ( phenobarbitone,
carbamazepine, rifampicin, smoking) Can occur within 2-3 days – 2 weeks and take same time to return to normal once stopped
Enzyme inhibitors ( ciprofloxacin, erythromycin, cimetidine) Can occur immediately. Care if drug has narrow therapeutic window .
Look for CYP450 interaction if cant explain ADRhttp://medicine.iupui.edu/clinpharm/ddis/
table.aspGenetic polymorphisms
![Page 25: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/25.jpg)
Enzyme Drug affected
Inducer Effect
CYP1A2 Duloxetine SmokingReduced effect(approx 50% lower
plasma concentrations)
CYP2C9 Celecoxib Carbamazepine Reduced effect
CYP2C19 Diazepam Carbamazepine Reduced effect
CYP3A4 MidazolamAlfentanilFentanylOxycodone
CarbamazepineHigh dose dexamethasone
Reduced effect
![Page 26: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/26.jpg)
Enzyme Drug affected
Inhibitor Effect
CYP1A2 Duloxetine CiprofloxacinPotentially toxic levels - avoid
CYP2C9 CelecoxibAmiodaroneFluconazole
Increased risk of AEs
CYP2C19 Diazepam OmeprazoleIncreased risk of sedation
CYP2D6
CodeineTramadol
Venlafaxine
ParoxetineFluoxetine
Reduced or no effect
Increased risk of AEs
CYP3A4Midazolam
Fentanyl
ClarithromycinBicalutamideGrapefruit juice
Increased risk of AEs
Increased absorption
![Page 27: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/27.jpg)
PHARMACOGENETICSPHARMACOGENETICS is the study of is the study of how variation in an individual gene how variation in an individual gene affects the response to drugs which affects the response to drugs which can lead to adverse drug reactions, can lead to adverse drug reactions, drug toxicity, therapeutic failure and drug toxicity, therapeutic failure and drug interactions.drug interactions.
TERMINOLOGYTERMINOLOGY
![Page 28: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/28.jpg)
POLYMORPHISMS refer to commonly occurring genetic variants (i.e. differences in DNA sequences).
In most cases, a polymorphism is of little clinical consequence.
However, a polymorphism in a critical coding or non-coding region can lead to altered protein synthesis with clinical implications such as abnormal drug responses.
![Page 29: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/29.jpg)
Genetic variability can affect an individual’s response to drug treatment by influencing pharmacokinetic and pharmacodynamic processes, e.g. cytochrome P450 isoenzymes, drug receptors, or transport proteins
![Page 30: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/30.jpg)
Several polymorphisms that affect drug metabolism have been identified ( poor hydroxylators and slow acetylators)
Functional changes as a result of a polymorphism can have profound effects: Adverse drug reactionToxicityLack of effectDrug interaction
![Page 31: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/31.jpg)
Isoenzymes CYP2D6, CYP2C9 and CYP2C19 display high levels of polymorphism
These have been shown to affect the response of individuals to many drugs
Codeine - Metabolised by CYP2D6 to morphine. PMs derive no analgesia from codeine. Drugs that inhibit CYP2D6 will mimic PMUltra Metabolisers are at risk of life-threatening adverse drug reactions as codeine is metabolised at a very high rate.
![Page 32: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/32.jpg)
Many drug interactions will go unrecognisedIf there is an unexpected change in patient’s
condition, suspect drug interaction as well as disease
Many drug interactions can develop insidiouslyOne size (dose) does not fit all!
Pharmacogenetics becoming more important
![Page 33: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/33.jpg)
ExcretionRenal – most drugs Biliary – ( lipid soluble – diethylstilbestrol) –
enterohepatic circulation increases bioavailability
Half life ( T1/2) Time to steady state concentration = 3 to 5
half lives Use PCF3 tables
![Page 34: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/34.jpg)
Steady State Concentration
![Page 35: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/35.jpg)
Dose adjustment in frail, elderly and kidsDiscussion ( this lecture does not cover
paediatric dosing)
![Page 36: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/36.jpg)
Dose adjustment in renal impairment
See separate Drugs and Renal Disease Lecture -Sue Ayers, April 2006 ( to be circulated via email)
Yorkshire Registrar Guidelines - Drug use in renal impairment
BNF/SPC/AYP –( ASK YOUR PHARMACIST)
Renal friendly opioids?
![Page 37: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/37.jpg)
Dose adjustment in Liver Disease See separate lecture ( To be circulated via
email) BASIC PRINCIPLES :
![Page 38: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/38.jpg)
Dose adjustment in disease progression and at the end of life Discussion
![Page 39: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/39.jpg)
Drug formularies in palliative care Discussion
![Page 40: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/40.jpg)
Managing a pharmacy budgetDiscussion EL94 (14) annex B and EL 95 ( Circulated by
email) PBC ( Practice based commisioning) PBR ( Payment by results) HRG ( Health Resources Groups) Tariff and non-tariff drugs ( high cost) ContractsSLAsCommissioning
![Page 41: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/41.jpg)
Prescribing issuesGMC - Good Medical Practice: Providing good
clinical care and Good Medical Practice: Maintaining & improving your performance
Other professional standards – NMC
http://www.nmc-uk.org/Publications/Standards/ RPS – MEP - http://www.rpharms.com/law-and-
ethics/medicines-ethics-and-practice-guide.asp
LOCAL MEDICINES MANAGEMENT POLICY !
![Page 42: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/42.jpg)
Prescribing issues 2Clinical Governance/ Risk Management NPSA http://www.npsa.nhs.uk/MHRA http://www.mhra.gov.uk/index.htm Taking drugs abroad
http://www.homeoffice.gov.uk/drugs/licensing/personal/ plus consulate of country visiting!
“letter from your prescribing doctor or drug worker, which must confirm your name, travel itinerary, names of prescribed controlled drugs, dosages and total amounts of each to be carried”
Personal License >3months supply
![Page 43: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/43.jpg)
Prescribing Issues – 3 Prescribing stationary FP10 – EXEMPTION
http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Prescriptioncosts.aspx
Near miss and drug incident reporting systems
Standard Resources to support prescribing
![Page 44: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/44.jpg)
OSCE fun !! The ultimate syringe driver /breakthrough
calculation The domiciliary syringe driver writing
nightmare! The “what schedule is this CD” game
![Page 45: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/45.jpg)
What schedule is this CDOxycontin 20mg in 2 ml InjectionZomorph 10mg capsules Lorazepam 1mg tablets Buprenorphine 10mcg/hr patch Oramorph 10mg/5mls liquid Buprenorphine 35mcg/hr patch Temazepam 20mg tablets Co-codamol 30/500 soluble tablets Midazolam 10mg in 2ml Injection
![Page 46: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/46.jpg)
FP10s for Controlled Drugs Comply with the requirements of the Misuse of Drugs Act. ( Handwritten or computer generated since 1995) In practice there are only extra requirements for Schedule 2 and Schedule 3 controlled drugs. Prescriptions for Schedule 4 and Schedule 5 controlled drugs just have to meet the requirements for writing prescriptions for POMs. FP10s for temazepam do not have to comply with the above requirements.Validity of prescriptions for schedule 2, 3 & 4 controlled drugs is now restricted to 28
![Page 47: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/47.jpg)
Schedule 2 and 3 CDs - Rx The prescriber's usual signature and the dateIf issued by a dentist, "for dental treatment only"The name and address of the patientThe dose of the drug to be takenIn the case of preparations, the form and, where appropriate, the strength of the preparationEither the total quantity of the preparation or the number of dose units in both words and figures“strong recommendation” that the maximum quantity is limited to 30 days for schedule 2, 3 & 4 controlled drugs.
![Page 48: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/48.jpg)
CDs post shipmanhttp://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4097904 ( Crown Report )
Safer Management of controlled drugs http://www.dh.gov.uk/en/AdvanceSearchResult/
index.htm?searchTerms=controlled+drugs Accountable Officer Registers Patent held register? SOPs
![Page 49: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/49.jpg)
Classifications of Adverse Drug Reactions
Mechanism (Type A vs Type B)
Type A: Dose dependent and predictable. (intolerance/side effects). About 80% of ADRs
Examples: Sedation with antipsychotic drugs. Hypokalaemia with diuretics. Liver failure with paracetamol overdose Theophylline toxicity when ciprofloxacin started
![Page 50: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/50.jpg)
Other Classifications
Type B: Not related to dose and usually not related to the pharmacology of the drug. Unpredictable
Examples: Allergic rash with amoxycillin (immune reaction –
“allergy” or “hypersensitivity”)
Renal failure with contrast dye for scans ( non- immune reaction - “idiosyncratic” )
![Page 51: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/51.jpg)
Type C: Chronic effects ( Benzo addiction)
Type D: Delayed effects ( carcinogens/teratogens)
Type E: End-of-treatment effects ( opiate withdrawal, beta blocker withdrawal – BP increase)
Type F: Failure of therapy ( Oral contraceptive and drug interaction)
![Page 52: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/52.jpg)
Anaphylaxis and emergency boxes http://www.resus.org.uk/pages/
anapost1.pdf#search="anaphylaxis” Policies! Information Naloxone – use in palliative care Verbal orders
![Page 53: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/53.jpg)
Unlicensed Drugs /Drugs beyond licenseSee PCF3Local policy Terminology Off label Unlicensed Drug Unlicensed use Information for patient
![Page 54: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/54.jpg)
Clinical Trials Good Clinical Practice http://www.mhra.gov.uk/Howweregulate/
Medicines/Inspectionandstandards/GoodClinicalPractice/index.htm
FAQs http://www.mhra.gov.uk/Howweregulate/
Medicines/Inspectionandstandards/GoodClinicalPractice/Frequentlyaskedquestions/index.htm
![Page 55: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/55.jpg)
Polypharmacy/ understanding medicinesDiscussion
![Page 56: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/56.jpg)
Classifications of Adverse Drug ReactionsClassification According to Severity
a) Mild – maybe not even noticed by patient. eg Raised LFTs with lots of drugs.
b) Moderate – requires corrective measures, but not hospitalisation. eg antibiotic rash.
c) Major – organ damage and hospitalisation likely. eg cholestatic jaundice with chlorpromazine.
d) Life threatening. eg pulmonary embolus caused by oral contraceptives.
![Page 57: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/57.jpg)
Classifications of Adverse Drug Reactions
Classification According to IncidenceEU classification:Used now for new SPC ( data sheets for medicines)
Very common More than 10%Example: Drowsiness with carbamazepine.
Common 1-10%Example: Fluid retention with carbamazepine.
Uncommon 0.1-1%Example: Diarrhoea with carbamazepine.
Rare 0.01-0.1%Example: Depression with carbamazepine.
Very Rare Less than 0.01%Example: Arrhythmias with carbamazepine.
The risk for an individual of dying during the year from any cause at all in the UK is about 1.1%.
![Page 58: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/58.jpg)
Organized by the Committee on Safety of Medicines (CSM) http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Reportingsuspectedadversedrugreactions/index.htm
“Yellow Cards” found at the back of the BNF or on-line
https://yellowcard.mhra.gov.uk/
Can be completed by doctor, pharmacist or nurse etc ….. caring for the patient … OR THE PATIENT!!!! ( on-line)
Facility to report available on SystmOne ..
![Page 59: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/59.jpg)
What Should be Reported?
All reactions to new drugs (they have an inverted black triangle next to them in BNF or MIMS).
Any serious reaction to all other drugs. Includes all prescription and OTC medicines. Includes vaccines, herbal products, blood products, dental
and surgical materials, X-ray contrast media.Not nutrition products or dressings. ( Device reporting : MHRA website)
![Page 60: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/60.jpg)
Drugs in syringe drivers Resources Syringe Driver Handbook Palliativedrugs.com – SDSDPalliative Care Mattershttp://www.pallcare.info/mod.php?
mod=sdrivers&menu=14
Mixing drugs in syringe drivers - issues Choice of syringe driver devices
![Page 61: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/61.jpg)
Drug interactions Discussion Resources
![Page 62: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/62.jpg)
Tolerance,dependance,addiction,discontinuation reactions Discussion
![Page 63: Pharmacology, Therapeutics and medicines management Sue Ayers Advanced Pharmacists Palliative Medicine March 2011](https://reader038.vdocument.in/reader038/viewer/2022102908/56649e115503460f94afd7ce/html5/thumbnails/63.jpg)
Accessing drugs in the community Discussion